[Long term follow-up after intracoranary brachytherapy due to in stent restenosis].
BACKGROUND
Intarcoronary brachytherapy with radioactive source is the method of choice to treat in stent restenosis. Currently, we have data available from randomized clinical trials, yet every day practice and routine results of barchytherapy are not completely defined.


METHODS
We studied 50 patients treated due to in stent restenosis. Procedures were performed by means of beta radiation, and the delivered dose was equal to 2000 cGy.


RESULTS
All patient were observed during hospitalization and long term follow-up (from 4 to 21 months). Diffuse and proliferative in stent restenosis (22.02 +/- 21.41 mm) was the most common type of lesions which were treated. Procedure success was 100%, and barchytherapy success was 98%. Median time of hospitalization was one day. Frequency of geographical miss was 7.8%. During in hospital period there were no cases of death, myocardial infarction nor need for revascularization. In long term follow-up 2 myocardial infarctions (4%), 1 bypass grafting (2%) and 9 target vessel revascularizations took place. The cumulative survival without event was 76%. Long term follow-up showed that adverse events occurred in the later period of observation, i.e., up to 6 months after brachytherpy. Median event free survival was 246.5 days.


CONCLUSIONS
Routine intracoronary brachytherapy due to in stent restenosis is safe and characterized by a high percentage of procedure success in long term follow-up.
II Klinika Kardiologii, Instytut Kardiologii Collegium Medicum Uniwersytetu Jagiellońskiego, Kraków. mbheba@cyf-kr.edu.pl
Grzegorz
G
Heba
Dariusz
D
Dudek
Dawid
D
Giszterowicz
Rafał
R
Depukat
Jacek
J
Legutko
Łukasz
Ł
Rzeszutko
Stanisław
S
Bartuś
Michał
M
Chyrchel
Marcin
M
Wizimirski
Jacek S
JS
Dubiel
D001918:Brachytherapy / Q000379:methods*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015607:Stents / Q000009:adverse effects*; D016896:Treatment Outcome